Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044531 | 0.89 | MAPK1 (0.55) | MAPK1MAPK3ROCK2ROCK1ATM | |
| SCHEMBL22043969 | 0.87 | MAPK1 (0.47) | MAPK1MAPK3ROCK2ROCK1ATM | |
| SCHEMBL22043979 | 0.85 | MAPK1 (0.51) | MAPK1MAPK3ROCK2ROCK1ATM | |
| SCHEMBL22044530 | 0.83 | MAPK1 (0.60) | MAPK1MAPK3 | |
| SCHEMBL22044844 | 0.82 | ITK (0.48) | MAPK1MAPK3ROCK2MAPK14 | |
| SCHEMBL22043985 | 0.82 | MAPK1 (0.48) | MAPK1MAPK3ROCK2ROCK1ATM | |
| SCHEMBL22043982 | 0.74 | MAPK1 (0.61) | MAPK1MAPK3ROCK2ROCK1MAPK14 | |
| SCHEMBL22044571 | 0.74 | ROCK2 (0.46) | MAPK1ROCK2ROCK1ATMMAPK14 | |
| SCHEMBL22043992 | 0.74 | MAPK1 (0.63) | MAPK1MAPK3ROCK2ROCK1P2RX7 | |
| SCHEMBL22044533 | 0.74 | ATM (0.44) | ROCK2ROCK1ATMP2RX7KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | MAPK1 3146/4885MAPK3 1726/4885ROCK2 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.